Minimally invasive therapies for prostatitis

Abstract

A plethora of reports describe a number of promising new minimally invasive treatment modalities available to patients with chronic prostatitis. This article reviews these studies, with most evaluating treatments using heat or intraprostatic injection. The results are difficult to compare because of the inconsistencies in study design, modalities of treatment, and outcome measures. Standard criteria for assessing symptom severity in chronic prostatitis recently have been developed and prospective clinical trials are underway to evaluate minimally invasive therapies for this debilitating condition. Until definitive data from these trials are available, minimally invasive therapies most likely will continue to be empirical and not a standard of care.

195 Intraprostatic Injection of Botulinum Toxin-A in Patients with Refractory Chronic Pelvic Pain Syndrome: The Transurethral vs. Transrectal Approach

“…Many treatment protocols have been assessed previously, e.g., a-blocker therapy and antimicrobial therapy, but have failed to provide an acceptable outcome [15][16][17][18][19][20][21], and the search for other drug regimens for such patients has gained favour among physicians [22,23].…”

Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach

“…The management of refractory CP/CPPS is frustrating and disappointing both for patients and physicians. Many treatment protocols have been assessed previously, e.g., α-blocker therapy and antimicrobial therapy, but have failed to provide an acceptable outcome [15–21] , and the search for other drug regimens for such patients has gained favour among physicians [22,23] .…”